Who
Jonathan Mark Hopper
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Vericel; Chief Medical Officer, Osiris Therapeutics.
In numbers
- Trades disclosed
- 194
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $7.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 12 Apr 2016
- Last trade
- 26 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 30 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $149K5,000 at $29.82 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $225K5,000 at $45.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $149K5,000 at $29.82 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $225K5,000 at $45.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $149K5,000 at $29.82 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $225K5,000 at $45.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $149K5,000 at $29.82 | filing |
| 26 Jun 2026filed 30 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $225K5,000 at $45.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $73K4,375 at $16.66 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $153K4,375 at $35.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —4,375 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —4,375 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $73K4,375 at $16.66 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $153K4,375 at $35.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $38K3,472 at $10.95 | filing |
| 2 Apr 2026filed 6 Apr 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $122K3,472 at $35.00 | filing |
News
No headline names them, or the companies they trade most, lately.